D
etecting rare sequence variation using high-throughput sequencing is fraught with pitfalls relating to sifting true variants from artifacts, as exemplified by a recent controversial study 1 of single-base changes in RNAs after transcription (RNA editing). Nature Biotechnology contacted several experts to discuss the current state of the detection of RNA editing events from RNA-seq data and the lessons that may apply to those facing similar analytical challenges, such as in the study of rare cells in a population or low-abundance splice variants.
Nature Biotechnology: How has RNA-seq been used to study RNA editing?
Heather Hundley: RNA-seq has primarily been used to catalog RNA editing sites in both the human and mouse transcriptomes, as well as small RNAs in Caenorhabditis elegans, mice and humans.
Brenda Bass: Most studies of RNA editing using RNA-seq have focused on the A-to-I type of editing, the most prevalent type of editing in the nuclear-encoded RNAs of animals. However, RNA-seq approaches have also been used to analyze RNA editing in transcripts encoded in organelle genomesfor example, those of plant chloroplast and Physarum polycephalum mitochondria.
Xinshu Grace Xiao:
The basic concept is quite simple. A mismatch between a genomic DNA sequence and an RNA transcribed from it is called a candidate RNA editing event if it is not a DNA variant or the result of a sequencing error. Therefore, most approaches involve mapping the RNA-seq reads to a genome, comparing DNA and RNA sequences and calling an RNA editing event. However, these seemingly straightforward steps are not as simple as they appear to be. Close attention H. Hundley: The ability to detect editing events in a large number of cellular targets makes identification of trends in editing patterns more apparent. Also, the methods can identify editing events that are rare, such as the small percentage of editing events present in miRNAs.
What barriers are there to wide adoption of high-throughput sequencing? B. Bass: High-throughput sequencingbased approaches are being widely adopted to answer questions that require a genomewide approach, such as "How many miRNAs are edited?" or "How many editing sites are there in human brain?" or "How many editing sites are there in plant mitochondria RNA?" However, most long-time researchers in the RNA editing field are focused on questions that are less amenable to these approachesspecifically, the biological implications of a single editing event in a certain mRNA, or the mechanism by which a certain type of editing is catalyzed by a specific enzyme.
J.B. Li:
The amount of data that has become available in the past few years is overwhelming for most researchers. And there is a lack of a user-friendly streamlined computational pipeline that combines the many steps required to achieve high specificity and sensitivity of calling RNA editing. Both of these barriers need to be addressed.
X.G. Xiao:
One main concern is still cost. Highthroughput sequencing is still expensive, and its application to RNA editing necessitates greater volume 30 number 12 DeCember 2012 nature biotechnology disease. For example, researchers found that two new RNA editing events alter amino acid sequence of COG3 and SRP9, and showed the possible important role of RNA editing plays in breast cancer 4 .
H. Hundley:
One noteworthy trend that came out of the ENCODE data was the finding that although the lists of genes with edited transcripts are similar between cell lines, the individual editing sites vary 5 . This suggests that it may be more important for a transcript to be 'marked' by editing than whether or not a specific adenosine undergoes deamination. Because A-to-I editing occurs within doublestranded (ds) regions of RNA, and dsRNAs are potent triggers of the antiviral response, editing may provide a critical means for preventing dsRNA structures within cellular transcripts from improperly activating the immune system. 3 . The lesson from his studies was that A-to-I editing sites were most abundant in noncoding regions of mRNAs, such as introns and untranslated regions, and that the doublestranded structures required for editing were formed by pairing of repetitive elements. In fact, these are the overriding lessons of most high-throughput sequencing approaches in the A-to-I editing field to date. Of course, I can't emphasize enough how wonderful it is to know all of the editing events on a genomewide basis! In my opinion, the most noteworthy insights into RNA editing as revealed by high-throughput sequencing are just starting to appear in the literature, and the best is yet to come. These future studies will not just define editing events in the transcriptome but evaluate how they change during development or, importantly, in disease. In this regard, changes in the levels of A-to-I editing in the brains of patients with certain neuronal diseases have been observed, but are hard to interpret owing to limiting material and small datasets. No doubt future high-throughput sequencing studies will address this.
Zhiyu Peng:
We have learned that RNA editing may play an important role in human X.G. Xiao: Errors in read mapping are by no means unique to RNA editing analysis. All applications of high-throughput sequencing are faced with mapping inaccuracies. However, the impact of such errors is particularly severe when the data are analyzed at single-nucleotide resolution or when low-abundance reads are sought after. Statistically, low-abundance reads more often reflect mapping errors than do high-abundance ones. Similar problems exist in other applications where low-abundance reads are relied upon to make interpretations. In contrast, there are applications that are more robust to mapping errors, such as the estimation of overall gene expression levels, where mapping errors normally affect a minor fraction of all reads of a gene.
How are these problems being addressed? J.B. Li: I believe that, in most cases, distinct approaches need to be developed for different problems. However, some unified efforts, such as accurate mapping of RNA-seq reads, can be generalized to different challenges where RNA-seq read mapping is a critical component.
For RNA editing, we and others have pinpointed some major sources of error [6] [7] [8] and subsequently developed new approaches to alleviate the problems 5,9-12 .
J. Pickrell:
There is unlikely to be a 'magic bullet' that solves these problems in a completely unified way. However, the similarities between the issues in, say, identifying RNA editing and identifying SNPs means that many lessons learned in one can be applied to the other. For example, tests for strand and position biases when calling variants from short reads have become standard in both situations.
What kinds of new technologies are needed?
J. Pickrell: Sequencing technologies that both provide long reads (thus avoiding many of the read mapping issues) and perform direct sequencing of RNA (rather than converting to cDNA) would dramatically decrease the falsepositive rates in these sorts of studies.
X.G. Xiao:
Deeper sequencing depth, once it's more affordable, will enable more rigorous statistical tests to make editing calls. In terms of algorithms, more stringent and accurate mapping approaches need to be developed. Easy-to-use analytic tools with proven accuracy and reliability could make RNA editing analysis a standard procedure in RNAseq data analysis. Z. Peng: Current pipelines cannot reliably call RNA editing events in genes that are expressed at low levels. L. Yang: As many transcriptome datasets are publicly available without a matched genome, new approaches are needed to predict RNA editing events in the absence of matching genomic DNA sequence.
What issues are most important for the field going forward? X.G. Xiao: We lack a gold standard data set to validate bioinformatically predicted RNA editing calls. The validation method used most often is Sanger sequencing of RT-PCR products, which is known to have limited sensitivity and low quantification accuracy. We have used clonal sequencing (where we clone RT-PCR products into vectors and Sanger sequence a large number of randomly picked clones), which can have great sensitivity and accuracy if enough clones are sequenced.
But the cost can be prohibitive.
There is a need for a unified effort to set up a gold standard database of RNA editing events. Perhaps we can choose a common cell line for which abundant RNA-seq data are available and collectively conduct deep clonal sequencing (or other experimental validation) on a subset of RNA editing sites (for example, 20-30 sites). All bioinformatic methods can then be applied to the RNA-seq data and benchmarked against the experimental gold standard.
J.B. Li:
The devil is in the details. This is very true in the recent debate on the RNA editing work. The multitude of existing RNA-seq read mapping tools, while seemingly sufficient for most applications of RNA-seq (for example, to gene expression levels, splicing junctions and fusion genes), perform poorly when challenged to look for single-base mismatches, such as RNA editing sites. A deeper understanding of computation, technology and biology can only be achieved by two-way communication between computational biologists and experimentalists.
